Literature DB >> 19883630

Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1.

Zhongxing Liang1, Hui Wu, James Xia, Yuhua Li, Yawei Zhang, Ke Huang, Nicholas Wagar, Younghyoun Yoon, Heidi T Cho, Stefania Scala, Hyunsuk Shim.   

Abstract

Multidrug resistance-associated protein (MRP-1/ABCC1) transports a wide range of therapeutic agents and may play a critical role in the development of multidrug resistance (MDR) in tumor cells. However, the regulation of MRP-1 remains controversial. To explore whether miRNAs are involved in the regulation of MRP-1 expression and modulate the sensitivity of tumor cells to chemotherapeutic agents, we analyzed miRNA expression levels in VP-16-resistant MDR cell line, MCF-7/VP, in comparison with its parent cell line, MCF-7, using a miRNA microarray. MCF-7/VP overexpressed MRP-1 mRNA and protein not MDR-1 and BCRP. miR-326 was downregulated in MCF-7/VP compared to MCF-7. Additionally, miR-326 was downregulated in a panel of advanced breast cancer tissues and consistent reversely with expression levels of MRP-1. Furthermore, the elevated levels of miR-326 in the mimics-transfected VP-16-resistant cell line, MCF-7/VP, downregulated MRP-1 expression and sensitized these cells to VP-16 and doxorubicin. These findings demonstrate for the first time the involvement of miRNAs in multidrug resistance mediated by MRP-1 and suggest that miR-326 may be an efficient agent for preventing and reversing MDR in tumor cells. Copyright 2009 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19883630     DOI: 10.1016/j.bcp.2009.10.017

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   6.100


  128 in total

Review 1.  Micro-RNAs and breast cancer.

Authors:  John Le Quesne; Carlos Caldas
Journal:  Mol Oncol       Date:  2010-04-28       Impact factor: 6.603

Review 2.  Shielding the messenger (RNA): microRNA-based anticancer therapies.

Authors:  Elena Sotillo; Andrei Thomas-Tikhonenko
Journal:  Pharmacol Ther       Date:  2011-04-14       Impact factor: 12.310

Review 3.  MicroRNA Pharmacoepigenetics: Posttranscriptional Regulation Mechanisms behind Variable Drug Disposition and Strategy to Develop More Effective Therapy.

Authors:  Ai-Ming Yu; Ye Tian; Mei-Juan Tu; Pui Yan Ho; Joseph L Jilek
Journal:  Drug Metab Dispos       Date:  2015-11-13       Impact factor: 3.922

Review 4.  Recent trends in microRNA research into breast cancer with particular focus on the associations between microRNAs and intrinsic subtypes.

Authors:  Sasagu Kurozumi; Yuri Yamaguchi; Masafumi Kurosumi; Miki Ohira; Hiroshi Matsumoto; Jun Horiguchi
Journal:  J Hum Genet       Date:  2016-07-21       Impact factor: 3.172

5.  Potential role of epigenetic mechanisms in the regulation of drug metabolism and transport.

Authors:  Magnus Ingelman-Sundberg; Xiao-Bo Zhong; Oliver Hankinson; Sudheer Beedanagari; Ai-Ming Yu; Lai Peng; Yoichi Osawa
Journal:  Drug Metab Dispos       Date:  2013-08-05       Impact factor: 3.922

6.  Chimeric MicroRNA-1291 Biosynthesized Efficiently in Escherichia coli Is Effective to Reduce Target Gene Expression in Human Carcinoma Cells and Improve Chemosensitivity.

Authors:  Mei-Mei Li; Balasubrahmanyam Addepalli; Mei-Juan Tu; Qiu-Xia Chen; Wei-Peng Wang; Patrick A Limbach; Janine M LaSalle; Su Zeng; Min Huang; Ai-Ming Yu
Journal:  Drug Metab Dispos       Date:  2015-05-01       Impact factor: 3.922

7.  Integrative nucleophosmin mutation-associated microRNA and gene expression pattern analysis identifies novel microRNA - target gene interactions in acute myeloid leukemia.

Authors:  Annika C Russ; Sandrine Sander; Sonja C Lück; Katharina M Lang; Marion Bauer; Frank G Rücker; Hans A Kestler; Richard F Schlenk; Hartmut Döhner; Karlheinz Holzmann; Konstanze Döhner; Lars Bullinger
Journal:  Haematologica       Date:  2011-08-31       Impact factor: 9.941

8.  MiRNA-26b inhibits cellular proliferation by targeting CDK8 in breast cancer.

Authors:  Jia Li; Xiaoyu Li; Xiangjie Kong; Qifeng Luo; Junfeng Zhang; Lin Fang
Journal:  Int J Clin Exp Med       Date:  2014-03-15

9.  Atorvastatin attenuation of ABCB1 expression is mediated by microRNA miR-491-3p in Caco-2 cells.

Authors:  Alice C Rodrigues; Elida Adalgisa Neri; Sidney Veríssimo-Filho; Nancy Amaral Rebouças; Rosario D C Hirata; Ai-Ming Yu
Journal:  Eur J Pharm Sci       Date:  2016-08-26       Impact factor: 4.384

Review 10.  Membrane microparticles: shedding new light into cancer cell communication.

Authors:  Paloma Silva de Souza; Roberta Soares Faccion; Paula Sabbo Bernardo; Raquel Ciuvalschi Maia
Journal:  J Cancer Res Clin Oncol       Date:  2015-08-19       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.